Abstract:Tuberculosis caused by Mycobacterium tuberculosis (Mtb), is a major factor of death around the world. Mtb protein tyrosine phosphatase B (MptpB), a virulent phosphatase encoded by Mtb, is a potential target for the treatment of tuberculosis. To explore the structure features of 134 indolin-2-on-3-spirothiazolidinones as MptpB inhibitors, in this work, a set of ligand-and receptor-based 3D-QSAR studies were, for the first time, carried out using comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) techniques. Splitting of the training and test sets was constructed by Kohonen's self-organizing map algorithm. Additionally, to profile the possible binding modes of these inhibitors, molecule docking and molecular dynamics (MD) simulations were performed as well. The optimal QSAR models built on both ligand-and receptor-based alignments exhibit proper reliabilities and predictive abilities as illustrated by their statistical results that for ligand-based alignment CoMFA and CoMSIA models obtain Q(2) = 0.662, R-ncv(2) = 0.799, R-pre(2) = 0.757, and Q(2) = 0.736, R-ncv(2) = 0.847, R-pre(2) = 0.866; whereas for docking-based one achieve Q(2) = 0.536, R-ncv(2) = 0.894, R-pre(2) = 0.823, and Q(2) = 0.498, R-ncv(2) = 0.812, R-pre(2) = 0.833, respectively. Furthermore, the contours generated from these models are well consistent with the docking and MD results we performed. Our findings are: (1) Indolin-2-on-3-spirothiazolidinones may bind to the MptpB with a "cockhorse" conformation, which is stabilized by eight H-bonds formed with the surrounding residues (Arg166, Cys160, Ala162, Lys164, His94 and Glu129), one cation-pi interaction with the side chain of Arg166 and two hydrophobic interactions in the binding site. (2) Introduction of bulky and electropositive substituents at R-3, hydrophobic substituents around rings A and E can improve the inhibition potency. (3) Nitro group at R-2 position of 2-oxindole core plays a crucial role for the biological activities, and may also be essential to the water-mediated H-bond networks. (4) For 8, 10-positions of the thiazolidinone ring and 13-position of isoxazole, the groups acting as H-bond acceptor are favorable for increasing the activity. All these results are expected to be useful in the discovery of novel and more potent MptpB inhibitors.

Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery

Synthesis, Characterization, and Biological Evaluation of New Derivatives Targeting MbtI as Antitubercular Agents

Integration of ligand and structure based approaches for identification of novel MbtI inhibitors in Mycobacterium tuberculosis and molecular dynamics simulation studies

Shedding X-ray Light on the Role of Magnesium in the Activity of Mycobacterium tuberculosis Salicylate Synthase (MbtI) for Drug Design

Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections

New Chromane-Based Derivatives as Inhibitors of Mycobacterium tuberculosis Salicylate Synthase (MbtI): Preliminary Biological Evaluation and Molecular Modeling Studies

Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors

Structure based virtual screening and discovery of novel inhibitors against FabD protein of Mycobacterium tuberculosis

Structure Determinants of Indolin-2-on-3-spirothiazolidinones As MptpB Inhibitors: an in Silico Study

Structure and inhibition mechanisms of Mycobacterium tuberculosis essential transporter efflux protein A

In silico analysis and characterization of potential inhibitors of MmaA3, a methoxy mycolic acid synthase from Mycobacterium tuberculosis

Identification of Novel Antimicrobial Compounds Targeting Mycobacterium tuberculosis S-Adenosyl-L-Homocysteine Hydrolase Using Dual Hierarchical In Silico Structure-Based Drug Screening

Exploring the Possible Binding Mode of Trisubstituted Benzimidazoles Analogues in Silico for Novel Drug Designtargeting Mtb FtsZ

Design of Novel Quinoline-Aminopiperidine Derivatives As Mycobacterium Tuberculosis (MTB) GyrB Inhibitors: an in Silico Study

The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling

Docking- and Pharmacophore-Based Virtual Screening for the Identification of Novel Mycobacterium Tuberculosis Protein Tyrosine Phosphatase B (mptpb) Inhibitor with a Thiobarbiturate Scaffold

Structure and Inhibition of Tuberculosinol Synthase and Decaprenyl Diphosphate Synthase from Mycobacterium Tuberculosis

Discovery and Evaluation of Novel Inhibitors of Mycobacterium Protein Tyrosine Phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic Acid Scaffold.

Identification of novel inhibitors for Prp protein of Mycobacterium tuberculosis by structure based drug design, and molecular dynamics simulations

Discovery of novel and potent InhA direct inhibitors by ensemble docking-based virtual screening and biological assays

A Molecular Dynamics Investigation of Mycobacterium tuberculosis Prenyl Synthases: Conformational Flexibility and Implications for Computer-aided Drug Discovery.